Alkem Laboratories Arm Intends to Acquire Up to 55% Stake in Occlutech Holding

Alkem MedTech, the medical devices arm of Alkem Laboratories, has announced a binding offer to acquire a majority stake in Switzerland-based Occlutech Holding AG.  

The move marks a strategic expansion into the global minimally invasive cardiac implant segment. 

Key Development 

Alkem MedTech intends to purchase up to a 55% stake in Occlutech for €99.4 million (about ₹1,074 crore). The target company specialises in minimally invasive cardiac implants and has an established presence across Europe and the US. 

Occlutech operates manufacturing and R&D facilities in Germany and Turkey, a global distribution hub in Sweden, and clinical operations in the United States.  

In calendar year 2025, it reported revenue of €49.4 million, delivering a three-year CAGR of 15.7%, with nearly 85% of revenue coming from Europe and the US markets.  

Management Commentary & Strategic Fit 

As per the exchange filings, B. N. Singh, Executive Chairman, Alkem Laboratories, said, “The acquisition of Occlutech opens up significant opportunities for Alkem MedTech, and reinforces Alkem’s long-term vision of becoming a global player in the medical devices industry, replicating its success story in pharma.” 

Kaustav Banerjee, CEO of Alkem MedTech, said, “Occlutech has established capabilities in structural heart devices, a highly-experienced management team, world class R&D and manufacturing facilities, and strong quality and regulatory framework, which provides a strong foundation for Alkem MedTech to begin its journey in the cardiology segment.”  

Impact & Outlook 

Through this transaction, Alkem MedTech gets entry into high-barrier cardiovascular device markets including the US, Japan and key Western European countries. The deal is expected to support its global scale-up strategy in advanced medical technology segments. 

Read More: Best Fundamentally Strong Stocks in February 2026 Based on 5-Year CAGR: BSE, TD Power Systems and More! 

Alkem Laboratories Share Price Performance  

As of February 14, 2026, Alkem Laboratories share price is closed at ₹5,400 per share, reflecting a decline of 8.01% from the previous closing price.  

Conclusion 

The Occlutech stake buy gives Alkem MedTech a fast-track entry into global cardiac devices and strengthens its long-term medtech expansion plan. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.